CD46 and cancer: Additionally, several different complement-regulatory proteins (CRPs) function to inhibit complement activation, and certain membrane-bound CRPs such as CD46, CD55, and CD59 were reported to be aberrantly expressed in various cancers (44–46), which likely confers resistance to CDC.